Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)

  • STATUS
    Recruiting
  • End date
    Jan 1, 2025
  • participants needed
    1990
  • sponsor
    Xiangtan Central Hospital
Updated on 5 November 2021
anemia
ejection fraction
heart failure
nt-probnp
b-type natriuretic peptide

Summary

The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.

Description

Study Description Brief Summary: The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.

Detailed Description: Heart failure is one of the most serious health concerns in the world, and it also remains the most common reason for hospitalization in older individuals. In patients with heart failure, anemia is associated with an increased risk of hospitalization and all-cause mortality. The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure (HF) events and cardiovascular death comparing to placebo in patients with reduced ejection fraction on top of standard of care.

This is an investigator-initiated, interventional, prospective, double-blind study. The primary objective is to investigate whether anemia correction is one of the prerequisites and determinants related to the beneficial effects of dapagliflozin in patients with heart failure. Impact of dapagliflozin treatment on hemoglobin level, heart failure-related readmission and all-cause death will be observed in comparison with placebo in heart failure patients receiving guideline recommended standard therapy during the 3months, 6 months and 1 year follow up.

Details
Condition Heart disease, Heart Failure, Anemia, Red Blood Cell Disorders, Cardiac Disease, Congestive Heart Failure, Heart Disease, Anemia; Non-Hodgkin’s Lymphoma, Blood disorder, anaemia, Heart failure, cardiac failure, congestive heart disease, Hematological Disorders
Treatment Placebo, Dapagliflozin
Clinical Study IdentifierNCT04707261
SponsorXiangtan Central Hospital
Last Modified on5 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female between the ages of 18 and 100 years
Elevated NT-proBNP or BNP levels on admission
Ejection fraction of 50% or less, and New York Heart Association (NYHA) class II, III, or IV symptoms

Exclusion Criteria

Treatment with SGLT2-i during the past 3 months of admission,or previous intolerance of an SGLT2 inhibitor
Severe (eGFR <30 mL/min/1.73 m^2 by CKD-EPI), unstable or rapidly progressing renal disease at the time of randomization
Pregnant or breast feeding female patients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note